A compound having formula (I) wherein G represents at least one substituent selected from the group consisting of C1-C12 alkyl and C1-C12 alkoxy.

A method for marking a petroleum hydrocarbon or a liquid biologically derived fuel by adding at least one compound having formula (I), wherein R1 and R2 independently represent hydrogen or C1-C4 alkyl groups, and G represents hydrogen or at least one substituent selected from the group consisting of C1-C18 alkyl and C1-C18 alkoxy.

The present disclosure relates to the technical field of degradation of persistent pollutants and discloses a method for efficiently degrading a perfluorinated compound (PFC), through which the problems of harsh reaction conditions and less high defluorination rate existing in prior-art methods for degrading PFCs are solved. In the present disclosure, a 3-indoleacetic acid (IAA) solution is irradiated with 254 nm UV light to generate hydrated electrons, with which the PFC are degraded by reduction under an aerobic condition, where an organo-modified montmorillonite is added to provide a reaction microzone, so the degradation and defluorination effects of the hydrated electrons for the PFC are greatly improved. The method for degrading a PFC according to the present disclosure is not affected by the pH of and the dissolved oxygen in the solution and less affected by the humic substances in a water body, thereby overcoming the defects in existing methods for degrading PFCs with hydrated electrons while the degradation efficiency is ensured. Therefore, the present disclosure is of great application value.

In some embodiments, the present disclosure pertains to a method for retrieving at least one molecular recognition element in a fixed tissue. In some embodiments the method comprises preparing a solution comprising at least one aldehyde-scavenging agent. In some embodiments, the method comprises contacting the fixed tissue with the solution. In some embodiments, the tissue is fixed with an aldehyde-based cross-linking agent. In some embodiments, a reaction of the aldehyde-scavenging agent with the aldehydes comprising the cross-linking agent retrieves the at least one molecular recognition t. In some embodiments, the at least one rolecular recognition element comprises of amino acids, peptides, proteins, nucleic acids, carbohydrates, lipids, or a combination thereof. In some embodiments, the at least one aldehyde-scavenging agent comprises of beta-dicarbonyl compounds, mono or di-amide scavengers, ethyl alcohols, sulfur containing compounds, mercaptoethylamines, mercaptoethanols, hydrazines, ethanolamines, hydroxylamines, anilines, variation of amines, activated charcoal, phenols, or mixtures and combinations thereof.

This month alone, Oakland-based, family-owned Mr. Espresso has already donated over 2,500 pounds of coffee to COVID-19 relief efforts all over the Bay Area.

During the first two weeks of April, the 42-year-old company — founded in Alameda by enterprising Italian-born Carlo Di Ruocco and now renowned as the first and currently only outfit in the nation that uses oak wood to roast its beans — has given coffee to the Alameda County Community Food Bank and San Francisco-Marin Food Bank, Frontline Foods, East Bay FeedER, Clinica de La Raza, St. Anthony’s Dining Room, Loaves and Fishes Family Kitchen, and other food-, health-, homeless-, youth-, and family-assistance programs.…

A compound represented by Formula 1 and an organic light-emitting device including the same are provided:

A polymer compound comprising a structural unit represented by the formula (1): wherein R1, R2, R3 and R4 each independently represent an alkyl group, an aryl group or a monovalent heterocyclic group, and these groups optionally have a substituent, two rings A may be the same or different, and represent a thiophene ring, a benzothiophene ring or a thienothiophene ring, n represents 1 or 2, and X represents a halogen atom, an alkyl group, an alkoxy group, an alkylthio group, an amino group, an aryl group, a monovalent heterocyclic group, an alkenyl group or an alkynyl group, and these groups optionally have a substituent, and when n is 2, two groups X may be the same or different.

The present disclosure provides a nitrogen-containing heterocyclic compound having a general formula (I) and an organic photoelectric apparatus thereof. The general formula (I) is wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10 are independently selected from a hydrogen atom, at least one compound having the general formula (II) and at least one compound having a general formula (III), wherein Y1, Y2, and Y3 are independently selected from C and N; and R3 and R4 are independently selected from C6-30 aromatic group and C2-30 heterocyclic aromatic group, wherein X is selected from oxyl group, sulfenyl group, substituted or non-substituted imino group, substituted or non-substituted methylene group, and substituted or non-substituted silicylene group, and R5, R6, R7, R8, R9, R10, R11, and R12 are independently selected from hydrogen, deuterium, C1-30 alkyl group, C6-30 aromatic group, and C2-30 heterocyclic aromatic group.

The present disclosure provides a nitrogen-containing heterocyclic compound having general formula (I) and an organic photoelectric apparatus thereof. where A1, A2, A3, A4, A5, A6, A7, and A8 are independently selected from a hydrogen atom, at least one compound having the general formula (II) and at least one compound having the general formula (III), where Y1, Y2, and Y3 are independently selected from C and N; R3 and R4 are independently selected from C6-30 aromatic group and C2-30 heterocyclic aromatic group, wherein X is selected from any one of oxyl group (—O—), sulfhydryl group (—S—), substituted or non-substituted imino group, substituted or non-substituted methylene group, and substituted or non-substituted silicylene group; R5, R6, R7, R8, R9, R10, R11, and R12 are independently selected from hydrogen, deuterium, C1-30 alkyl group, C6-30 aromatic group, or C2-30 heterocyclic aromatic group.

The present specification provides a hetero-cyclic compound and an organic light emitting device including the hetero-cyclic compound.

A compound represented by the following formula (1):

A compound includes a benzofuropyrimidine skeleton or a benzothienopyrimidine skeleton, a first substituent, and a second substituent. Each of the first substituent and the second substituent includes a furan skeleton, a thiophene skeleton, or a pyrrole skeleton. The first substituent is bonded to a pyrimidine ring included in the benzofuropyrimidine skeleton or a pyrimidine ring included in the benzothienopyrimidine skeleton. The second substituent is bonded to a benzene ring included in the benzofuropyrimidine skeleton or a benzene ring included in the benzothienopyrimidine skeleton. The light-emitting element includes the compound.

The present disclosure provides a nitrogen-containing heterocyclic compound having a general formula (I) and an organic photoelectric apparatus thereof. The compound of general formula (I) is: wherein A1, A2, A3, and A4 are independently selected from a hydrogen atom, a function group having a general formula (II); A1, A2, A3, and A4 include at least one function group having the general formula (II); R1 and R2 are independently selected from one of hydrogen, deuterium, C1-30 alkyl group, C6-30 aromatic group and C2-30 heterocyclic aromatic group; Y1 and Y2 are independently selected from substituted or non-substituted C and N,the general formula (II) being: wherein X is selected from one of oxyl group (—O—), sulfhydryl group (—S—), substituted or non-substituted imino group, substituted or non-substituted methylene group, and substituted or non-substituted silicylene group; and R3, R4, R5, R6, R7, R8, R9, and R10 are independently selected from one of hydrogen, deuterium, C1-30 alkyl group, C6-30 aromatic group, and C2-30 heterocyclic aromatic group.

The present disclosure provides a nitrogen-containing heterocyclic compound having a general formula (I) and an organic photoelectric apparatus thereof. The general formula (I) is: wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10 are independently selected from a hydrogen atom, a nitrile group and a function group having a general formula (II), and A1, A2, A3, A4, A5, A6, A7, A8, A9, and A10 include at least one nitrile group and at least one function group having the general formula (II),the general formula (II) being: wherein R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from hydrogen atoms, deuterium atoms, C6-30 aromatic group and C2-30 heterocyclic aromatic group.

A condensed cyclic compound represented by Formula 1: Ar1-L1-L2-Ar2 Formula 1 wherein in Formula 1, Ar1, Ar2, L1, and L2 are the same as described in the specification.

A compound is represented by Formula 1 and an organic light-emitting device including the same: wherein Formula 1 is the same as described above.

A component for a gas turbine engine including a gas path wall having a first surface and a second surface. A cooling hole extends through the gas path wall from an inlet in the first surface through a transition to an outlet in the second surface. Cusps are formed on the transition.

The present invention relates to an optical clear resin and a method for producing a liquid optical clear photo-curable adhesive.

A new study from Yale University found some users of the popular e-cigarette brand Juul might be inhaling unexpected chemicals.

A personal support worker (PSW), who has worked for a decade in long-term care homes, told White Coat, Black Art the COVID-19 pandemic is a crisis on top of an already existing crisis for PSWs.

A prodigiously talented, goal-scoring genius of the Long-Rioli family is just one of the dozens of men and women left confused and shocked by the AFL's decision to close the Northern Territory's only top-level side.

Canberra's jail still houses men and women together and newly released documents show corrections do not know whether prisoners have been meeting for clandestine affairs.

Compound interest will be one of the most important things you ever learn. Don't believe it? Gen Fricker will explain why. Learn how compound interest works, and why saving now can help you later. Game changer! Then test yourself with ASIC Moneysmart's "Things to think about" classroom exercises.

A new study suggests a half-ton bird roamed Europe nearly 2 million years ago, around when our Homo predecessors were first entering the region.

Coronavirus: While food banks struggle, L.A.'s schools are feeding the hungry

This classic pound cake recipe follows the one-to-one ratios of butter, sugar, flour and eggs and is flavored with vanilla.

This easy pound cake recipe relies on the classic formula of equal weight ratios of butter, sugar, eggs and flour for a fine-crumbed cake that keeps and packs well.

The oceanfront home of billionaire philanthropist Eli Broad is for sale in Malibu at $75 million.

Actress-producer Eva Longoria has sold her Hollywood Hills compound, which was previously owned by actor Tom Cruise, for $8.25 million.

A Nashville mom who gave birth to an 'alarmingly small' child celebrates her first Mother's Day with a healthy daughter and waves of gratitude.

Gov. Mike Pence's Scott County order allowing a needle-exchange program is a welcome step. But it's just a start.

The pound falls to its lowest level against the dollar since 1985, trading at $1.15.

The plasmas of diabetic or uremic patients and of those receiving peritoneal dialysis treatment have increased levels of the glucose-derived dicarbonyl metabolites like methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG). The elevated dicarbonyl levels can contribute to the development of painful neuropathies. Here, we used stimulated immunoreactive Calcitonin Gene–Related Peptide (iCGRP) release as a measure of nociceptor activation, and we found that each dicarbonyl metabolite induces a concentration-, TRPA1-, and Ca2+-dependent iCGRP release. MGO, GO, and 3-DG were about equally potent in the millimolar range. We hypothesized that another dicarbonyl, 3,4-dideoxyglucosone-3-ene (3,4-DGE), which is present in peritoneal dialysis (PD) solutions after heat sterilization, activates nociceptors. We also showed that at body temperatures 3,4-DGE is formed from 3-DG and that concentrations of 3,4-DGE in the micromolar range effectively induced iCGRP release from isolated murine skin. In a novel preparation of the isolated parietal peritoneum PD fluid or 3,4-DGE alone, at concentrations found in PD solutions, stimulated iCGRP release. We also tested whether inflammatory tissue conditions synergize with dicarbonyls to induce iCGRP release from isolated skin. Application of MGO together with bradykinin or prostaglandin E2 resulted in an overadditive effect on iCGRP release, whereas MGO applied at a pH of 5.2 resulted in reduced release, probably due to an MGO-mediated inhibition of transient receptor potential (TRP) V1 receptors. These results indicate that several reactive dicarbonyls activate nociceptors and potentiate inflammatory mediators. Our findings underline the roles of dicarbonyls and TRPA1 receptors in causing pain during diabetes or renal disease.

The plasmas of diabetic or uremic patients and of those receiving peritoneal dialysis treatment have increased levels of the glucose-derived dicarbonyl metabolites like methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG). The elevated dicarbonyl levels can contribute to the development of painful neuropathies. Here, we used stimulated immunoreactive Calcitonin Gene–Related Peptide (iCGRP) release as a measure of nociceptor activation, and we found that each dicarbonyl metabolite induces a concentration-, TRPA1-, and Ca2+-dependent iCGRP release. MGO, GO, and 3-DG were about equally potent in the millimolar range. We hypothesized that another dicarbonyl, 3,4-dideoxyglucosone-3-ene (3,4-DGE), which is present in peritoneal dialysis (PD) solutions after heat sterilization, activates nociceptors. We also showed that at body temperatures 3,4-DGE is formed from 3-DG and that concentrations of 3,4-DGE in the micromolar range effectively induced iCGRP release from isolated murine skin. In a novel preparation of the isolated parietal peritoneum PD fluid or 3,4-DGE alone, at concentrations found in PD solutions, stimulated iCGRP release. We also tested whether inflammatory tissue conditions synergize with dicarbonyls to induce iCGRP release from isolated skin. Application of MGO together with bradykinin or prostaglandin E2 resulted in an overadditive effect on iCGRP release, whereas MGO applied at a pH of 5.2 resulted in reduced release, probably due to an MGO-mediated inhibition of transient receptor potential (TRP) V1 receptors. These results indicate that several reactive dicarbonyls activate nociceptors and potentiate inflammatory mediators. Our findings underline the roles of dicarbonyls and TRPA1 receptors in causing pain during diabetes or renal disease.

VOLUME 295 (2020) PAGES 3285–3300An incorrect graph was used in Fig. 5C. This error has now been corrected. Additionally, some of the statistics reported in the legend and text referring to Fig. 5C were incorrect. The F statistics for Fig. 5C should state Fken(3,16) = 7.454, p < 0.01; FCCCP(1,16) = 102.9, p < 0.0001; Finteraction(3,16) = 7.480, p < 0.01. This correction does not affect the results or conclusions of this work.jbc;295/17/5835/F5F1F5Figure 5C.

The increasing incidence of antimalarial drug resistance to the first-line artemisinin combination therapies underpins an urgent need for new antimalarial drugs, ideally with a novel mode of action. The recently developed 2-aminomethylphenol, JPC-3210, (MMV 892646) is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and favorable preclinical pharmacokinetics including a lengthy plasma elimination half-life. To investigate the impact of JPC-3210 on biochemical pathways within P. falciparum-infected red blood cells, we have applied a "multi-omics" workflow based on high resolution orbitrap mass spectrometry combined with biochemical approaches. Metabolomics, peptidomics and hemoglobin fractionation analyses revealed a perturbation in hemoglobin metabolism following JPC-3210 exposure. The metabolomics data demonstrated a specific depletion of short hemoglobin-derived peptides, peptidomics analysis revealed a depletion of longer hemoglobin-derived peptides, and the hemoglobin fractionation assay demonstrated decreases in hemoglobin, heme and hemozoin levels. To further elucidate the mechanism responsible for inhibition of hemoglobin metabolism, we used in vitro β-hematin polymerization assays and showed JPC-3210 to be an intermediate inhibitor of β-hematin polymerization, about 10-fold less potent then the quinoline antimalarials, such as chloroquine and mefloquine. Further, quantitative proteomics analysis showed that JPC-3210 treatment results in a distinct proteomic signature compared with other known antimalarials. While JPC-3210 clustered closely with mefloquine in the metabolomics and proteomics analyses, a key differentiating signature for JPC-3210 was the significant enrichment of parasite proteins involved in regulation of translation. These studies revealed that the mode of action for JPC-3210 involves inhibition of the hemoglobin digestion pathway and elevation of regulators of protein translation. Importantly, JPC-3210 demonstrated rapid parasite killing kinetics compared with other quinolones, suggesting that JPC-3210 warrants further investigation as a potentially long acting partner drug for malaria treatment.

26 September 2019

Timothy D Rohrbach
Apr 27, 2020; 0:jlr.D120000809v1-jlr.D120000809
Methods

Mass spectrometry (MS) assisted lipidomic tissue analysis is a valuable tool to assess sphingolipid metabolism dysfunction in disease. These analyses can reveal potential pharmacological targets or direct mechanistic studies to better understand the molecular underpinnings and influence of sphingolipid metabolism alterations on disease etiology. But procuring sufficient human tissues for adequately powered studies can be challenging. Therefore, biorepositories, which hold large collections of cryopreserved human tissues, are an ideal retrospective source of specimens. However, this resource has been vastly underutilized by lipid biologists, as the components of optimal cutting temperature compound (OCT) used in cryopreservation are incompatible with MS analyses. Here, we report results indicating that OCT also interferes with protein quantification assays, and that the presence of OCT impacts the quantification of extracted sphingolipids by LC–ESI–MS/MS. We developed and validated a simple and inexpensive method that removes OCT from OCT-embedded tissues. Our results indicate that removal of OCT from cryopreserved tissues does not significantly affect the accuracy of sphingolipid measurements with LC–ESI–MS/MS. We used the validated method to analyze sphingolipid alterations in tumors compared with normal adjacent uninvolved lung tissues from individuals with lung cancer, and to determine the long-term stability of sphingolipids in OCT-cryopreserved normal lung tissues. We show that lung cancer tumors have significantly altered sphingolipid profiles and that sphingolipids are stable for up to 16 years in OCT-cryopreserved normal lung tissues. This validated sphingolipidomic OCT-removal protocol should be a valuable addition to the lipid biologist’s toolbox.

VOLUME 295 (2020) PAGES 3285–3300An incorrect graph was used in Fig. 5C. This error has now been corrected. Additionally, some of the statistics reported in the legend and text referring to Fig. 5C were incorrect. The F statistics for Fig. 5C should state Fken(3,16) = 7.454, p < 0.01; FCCCP(1,16) = 102.9, p < 0.0001; Finteraction(3,16) = 7.480, p < 0.01. This correction does not affect the results or conclusions of this work.jbc;295/17/5835/F5F1F5Figure 5C.

OBJECTIVE

To determine the relationship between ATP7B mutations and diabetes in Wilson disease (WD).

Peng Shi, Zifeng Zhao.

Source: The Annals of Applied Statistics, Volume 14, Number 1, 357--380.

Abstract:
In actuarial research a task of particular interest and importance is to predict the loss cost for individual risks so that informative decisions are made in various insurance operations such as underwriting, ratemaking and capital management. The loss cost is typically viewed to follow a compound distribution where the summation of the severity variables is stopped by the frequency variable. A challenging issue in modeling such outcomes is to accommodate the potential dependence between the number of claims and the size of each individual claim. In this article we introduce a novel regression framework for compound distributions that uses a copula to accommodate the association between the frequency and the severity variables and, thus, allows for arbitrary dependence between the two components. We further show that the new model is very flexible and is easily modified to account for incomplete data due to censoring or truncation. The flexibility of the proposed model is illustrated using both simulated and real data sets. In the analysis of granular claims data from property insurance, we find substantive negative relationship between the number and the size of insurance claims. In addition, we demonstrate that ignoring the frequency-severity association could lead to biased decision-making in insurance operations.

Michael V. Boutsikas, Eutichia Vaggelatou

Source: Bernoulli, Volume 16, Number 2, 301--330.

Abstract:
Let X 1 , X 2 , …, X n be a sequence of independent or locally dependent random variables taking values in ℤ + . In this paper, we derive sharp bounds, via a new probabilistic method, for the total variation distance between the distribution of the sum ∑ i =1 n X i and an appropriate Poisson or compound Poisson distribution. These bounds include a factor which depends on the smoothness of the approximating Poisson or compound Poisson distribution. This “smoothness factor” is of order O( σ −2 ), according to a heuristic argument, where σ 2 denotes the variance of the approximating distribution. In this way, we offer sharp error estimates for a large range of values of the parameters. Finally, specific examples concerning appearances of rare runs in sequences of Bernoulli trials are presented by way of illustration.

Eitan Greenshtein, Ya’acov Ritov.

Source: Statistical Science, Volume 34, Number 2, 224--228.

Abstract:
We present some personal reflections on empirical Bayes/ compound decision (EB/CD) theory following Efron (2019). In particular, we consider the role of exchangeability in the EB/CD theory and how it can be achieved when there are covariates. We also discuss the interpretation of EB/CD confidence interval, the theoretical efficiency of the CD procedure, and the impact of sparsity assumptions.

The rock crash-landed in the Sahara Desert after a presumed collision chipped it off the lunar surface